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Summary
Inherited disorders of platelet function are a rare and 
heterogeneous group of diseases usually characterised 
by a mild to moderate bleeding tendency. Typical bleed-
ing symptoms are easy bruising, epistaxis, menorrhagia 
as well as mucocutaneous and perioperative bleeding. 
The performance of platelet function diagnostics in chil-
dren is hampered by age-dependent restriction of blood 
sample size, poor venous access, and the lack of repro-
ducible test reference ranges for children of different age 
groups. Platelet function testing is limited to specialised 
centres, because platelet function test procedures are 
complicated and time-consuming, which most likely re-
sults in a relevant number of undiagnosed and incor-
rectly classified children with clinically relevant platelet 
function defects. Evaluation of bleeding history and 
bleeding symptoms is essential for a rational step-by-
step approach to diagnosis. Platelet function diagnostics 
should be preceded by the exclusion of thrombocytope-
nia, von Willebrand disease, and secondary haemostasis 
defects. Light transmission aggregometry is still consid-
ered the standard for the assessment of platelet func-
tion. Every effort should be made to classify the specific 
platelet function defect in the patient, because this is es-
sential for accurate treatment and counselling.
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Zusammenfassung
Angeborene Thrombozytenfunktionsstörungen stellen 
eine seltene und heterogene Gruppe von Erkrankungen 
dar, welche meist durch eine leichte bis mittelschwere 
Blutungsneigung auffallen. Typische Blutungssymptome 
sind Hämatomneigung, Epistaxis, Menorrhagien sowie 
Schleimhaut- und perioperative Blutungen. Die Durch-
führung der Thrombozytenfunktionsdiagnostik bei Kin-
dern wird erschwert durch die altersabhängig begrenzte 
Blutprobenmenge, schwierige Venenverhältnisse und 
das Fehlen von Referenzbereichen für Kinder unter-
schiedlichen Alters. Aufgrund der meist komplizierten 
und zeitaufwendigen Tests ist die Thrombozytendiag-
nostik auf spezialisierte Zentren begrenzt. Mit hoher 
Wahrscheinlichkeit wird eine relevante Anzahl von Kin-
dern mit nichtdiagnostizierten bzw. unkorrekt klassifizier-
ten, klinisch relevanten Thrombozytopathien übersehen. 
Die Erhebung der Blutungsanamnese und die Bewertung 
der Blutungssymptome sind erforderlich für eine stufen-
weise erfolgreiche Gerinnungsdiagnostik. Vor Durchfüh-
rung einer Thrombozytenfunktionsdiagnostik sollten 
das Vorliegen einer Thrombozytopenie, einer von-Wille-
brand-Erkrankung und sekundärer Gerinnungsstörungen 
ausgeschlossen werden. Die Lichttransmissionsaggrego-
metrie gilt noch immer als Standardmethode für die Be-
urteilung der Thrombozytenfunktion. Nach Möglichkeit 
sollte stets versucht werden, den vorliegenden spezifi-
schen Thrombozytenfunktionsdefekt zu klassifizieren, da 
dies für eine adäquate Behandlung und eine gezielte 
 genetische Beratung notwendig ist.
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Standardised Questionnaires for Identification of 
 Children with Bleeding Disorders
In general, laboratory tests for haemostasis are ordered on 
the basis of bleeding symptoms and/or a positive bleeding his-
tory. In order to identify, diagnose, and treat children at risk 
for bleeding, including taking general clinical steps to prevent 
bleeding, a detailed family and individual history of bleeding 
type and severity is crucial, particularly when proper classifi-
cation of the underlying haemostasis disorder is lacking. 
The significance of compiling a standardised bleeding his-
tory by using a structured questionnaire for preoperative 
bleeding risk assessment in children has been well docu-
mented, but only few questionnaires have focused on the de-
tection of haemostatic disorders in children [8–10]. Question-
naires for diagnosis of haemostatic disorders are voluminous 
and time-consuming and have not been introduced into clini-
cal practice so far [11, 12].
 
Severe haemophilia is typically associated with haemar-
throses; muscle bleeds and intracranial bleeds are rare. By 
contrast, platelet defects primarily result in easy bruising, 
epistaxis, mucosal and oral cavity bleeding, invasive proce-
dure-related bleeding, and menorrhagia in older girls. Clinical 
diagnosis is often difficult since easy bruising and epistaxis are 
also common in healthy children [13]. Most affected children 
display only few bleeding symptoms, which underlines the im-
portance of evaluating their family history. The THROMKID 
Quality Project revealed that the family bleeding history was 
conspicuous in more than half of the children with PFD [14]. 
Algorithm for Diagnosis of Inherited Haemostatic 
 Disorders in Clinical Practice
Children with severe or prolonged bleeding and/or unex-
plained bleeding and/or a positive individual and/or family 
 history of bleeding should undergo coagulation testing. The 
 algorithm shown in figure 1 incorporates the results of the 
THROMKID Quality Project, in which cooperating centres 
reported the diagnostic approach to children with suspected 
inherited defects of platelet function and bleeding of unknown 
cause. The cooperating centres reported a similar approach 
 irrespective of the clinical scenario, including acute bleeding 
and positive, individual, and family history of bleeding [15].
Before testing platelet function, the following must be 
 excluded: medication interfering with haemostasis such as 
NSAR, severe infection, immune thrombocytopenia, and 
 defects of secondary haemostasis such as haemophilia A/B 
and von Willebrand disease as the most common hereditary 
haemorrhagic disorder. It must always be remembered that 
many inherited platelet disorders are associated with low 
platelet counts [16]. Some platelet defects are associated with 
wide-ranging symptom complexes that include defects of the 
immune system, hearing loss, albinism, impairment of renal 
Introduction
Inherited platelet function defects (PFD) are a rare and het-
erogeneous group of disorders [1]. Bleeding symptoms differ 
widely. Due to the fact that the majority of affected patients 
present with a mild to moderate bleeding tendency, many pa-
tients are not diagnosed during childhood. However, follow-
ing trauma and surgery unexpected extensive bleeding may 
occur. For this reason, when normal coagulation screening re-
sults are accompanied by unexplained conspicuous bleeding 
symptoms, testing for PFD is mandatory [2, 3]. 
However, selection and performance of tests of platelet 
function may be difficult in children. For most tests, accurate 
and generalisable reference ranges for children of different 
age groups have not yet been determined. Poor venous access 
and restrictions in blood sample size, especially in younger 
children with suspected platelet disorders, frequently hinder a 
complete laboratory work-up [3]. 
Testing for platelet function is performed only by a rela-
tively small number of highly specialised laboratories, often 
affiliated with major hospitals and clinics. Consequently, diag-
nosed cases are frequently clustered around such laboratories, 
while elsewhere an unknown but probably relevant number of 
cases remain undiagnosed or incorrectly classified [4, 5]. 
This article summarises current knowledge on the diag-
nostic approach to children with suspected inherited disor-
ders of platelet function. Presented information includes 
data from the THROMKID Quality Project of the Perma-
nent Paediatric Group of the German Thrombosis and 
 Haemostasis Research Society (GTH). The main part of this 
study was a collaborative patterns-of-practice survey in-
tended to overview diagnosis and treatment of patients with 
functional platelet abnormalities in Austria, Germany, and 
Switzerland [6, 7]. 
Incidence of Inherited Thrombocytopathies
Most disorders of platelet function are described in a very 
small number of patients. The true incidence is still un-
known [4]. Due to the mild to moderate bleeding tendency 
in most affected children, defects may frequently remain 
undiagnosed until the haemostatic system is challenged, e.g. 
during major surgery. The THROMKID Quality Project 
revealed 1.3–2.2 affected children per one million inhabit-
ants in the German-speaking countries [7]. Only in about 
half (n = 122) of the 215 identified children were defects 
well-classified. Of these children, 39 (32%) presented with 
Glanzmann thrombasthenia, followed by aspirin-like de-
fects (n = 26, 21%), platelet receptor defects (n = 20, 17%), 
storage pool disorders (n = 18, 15%), Bernard-Soulier syn-
drome (n = 10, 8%), Hermansky-Pudlak syndrome (n = 6, 
5%), and MYH9-related macrothrombocytopenia syn-
dromes (n = 3, 2%). 
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For clinical decision-making, clinicians are well advised to 
rely on their clinical judgement and on a limited number of 
preferably simple, robust, and available tests at their centre. 
In many cases this line of action will at least confirm or rule 
out the tentative diagnosis of a PFD. However, every effort 
should be made to classify the specific PFD using highly spe-
cialised assays such as electron microscopy and molecular 
 genetic methods [20, 21]. Classification of PFDs is essential 
for accurate counselling and treatment.
Most of the specific platelet function testing methods re-
cently described by authors in great detail are difficult to per-
form, time-consuming, and need freshly drawn samples of 
 venous blood [22]. However, the initial steps in investigating 
platelet function disorders – the determination of platelet 
count and the assessment of mean platelet size – may be per-
formed with any commonly used automated counter. Refer-
ence ranges for platelet count and mean platelet volume in 
children do not differ from those for adults. Just recently, Al-
thaus et al. [23] published a new method for diagnosing struc-
tural platelet defects such as congenital macrothrombocyto-
penic disorders from peripheral blood smears, which are easy 
to obtain even in very young children. 
Light transmission aggregometry (LTA) is poorly stand-
ardised and requires relatively large volumes of freshly drawn 
blood, but is still considered the ‘gold standard’ for the evalu-
ation of platelet function; this was confirmed by the THROM-
KID Quality Project [6, 24]. Recently, the Clinical and Labo-
ratory Standards Institute (CLSI), the Platelet Physiology 
Subcommittee of the SSC of the International Society on 
Thrombosis and Haemostasis (ISTH), and the North Ameri-
can Specialised Coagulation Laboratory Association (NAS-
COLA) published extensive surveys and guidelines on the 
standardisation of LTA [25–27]. In healthy children older 
function, and other symptoms [4]. Application of the algo-
rithm can support and guide clinicians in identifying and clas-
sifying the suspected haemostatic defect (fig. 1).
The THROMKID Quality Project, performed in coagula-
tion laboratories in German-speaking countries, revealed that 
specific testing of platelet function is often preceded by 
screening tests for primary haemostasis, such as the in vivo 
bleeding time (BT), the Platelet Function Analyzer (PFA) 
100® test, and thrombelastography. However, these tests are 
of limited value. The in vivo bleeding time is a time-consum-
ing test that requires an experienced operator and patient co-
operation, something often lacking in children. Studies have 
not clearly established the ability of BT to predict an individu-
al’s bleeding risk [17, 18]. Many centres have replaced the in 
vivo BT with the PFA 100®, but the test lacks speciﬁcity as a 
screening tool for platelet disorders [2, 19]. Thrombelastogra-
phy has been shown to be useful as a point-of-care means of 
assessing perioperative coagulability as well as guiding and 
 reducing replacement therapy for blood loss and dilutional 
coagulopathy. The use of this test for screening for platelet 
defects is also limited because of its lacking specificity.
Algorithm for Diagnosis of Inherited Platelet Function 
Disorders in Clinical Practice
Determination of platelet function in children does not essen-
tially differ from that in adult patients. The limited blood vol-
ume available calls for an algorithm for choosing appropriate 
platelet tests (fig. 1, table 1). In the case of newborns and in-
fants without bleeding symptoms, but with a conspicuous fam-
ily history, it may be preferable to start testing in possibly af-
fected adult family members and to defer testing in the child. 
testing for defects of 
secondary haemostasis 
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Bleeding symptoms and/or positive bleeding history 
(acquired haemostatic disorders by infection, medication etc. excluded) Fig. 1. Algorithm 
for diagnostic ap-
proach to children 
with suspected 
inherited disorders 
of platelet function. 
aDetailed algorithm 
in [4]. bDetailed algo-
rithm in [16]. aPTT 
= Activated partial 
thromboplastin time; 
VWF:Ag = von 
Willebrand factor 
antigen; VWD = von 
Willebrand disease; 
PT = prothrombin 
time, VWF: CB = 
collagen binding 
activity; VWF:RCo 
= Ristocetin cofac-
tor; ITP = immune 
thrombocytopenia.
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Value of commonly used tests for  
diagnosis of inherited platelet defects
(poor ‘–’; fair ‘0’; good ‘+’)
Basic test panel
(orientation; rational approach)
Extended test panel
(confirmation/characterisation approach)
Standard microscopy of stained  
blood smears ‘+’
PFA 100-test ‘–’
In vivo bleeding time ‘–’
Thrombelastography ‘–’
LTA ‘+’
IA ‘0’
Luminometry ‘+’
Flow cytometry ‘+’
Electron microscopy ‘+’
Genetics ‘0’ 
platelet counting (counter) platelet secretion (luminometric  
determination of ATP release, serotonin- 
releasing assay, mepacrine uptake)
platelet volume and platelet size 
determination (counter and  
blood smear examination)
platelet glycoprotein expression flow  
cytometry
platelet aggregation (LTA or IA 
using a panel of different  
agonists – ADP, arachidonic acid, 
or epinephrine, collagen)
platelet ultrastructure / morphology  
(electron microscopy, immuno- 
fluorescence microscopy, confocal  
microscopy)
platelet adhesion assays genetic analysis (molecular genetics  
methods) 
ADP = Adenosine diphosphate; LTA = light transmission aggregometry; ATP = adenosine triphosphate;  
PFA = platelet function analyzer; IA = impedance aggregometry.
Table 1. Stratifica-
tion of platelet tests 
for diagnosis of 
inherited platelet 
function defects in 
children
Table 2. Refer-
ence values for light 
transmission ag-
gregometry / adeno-
sine triphosphate 
(ATP) release using 
the Chrono-log 
lumi-aggregometer 
(Chrono-log Corp., 
Havertown, PA, 
USA) in platelet 
rich plasma from 
healthy children 
and adults. Final 
concentrations of 
agonists are stated 
in brackets. Values 
are expressed as 
median of maximal 
percentage aggregation within 6 min after addition of agonist with the interval covering 95% of the population studied (between 2.5th and 97.5th 
 centiles); table modified from [29]
Group 1–5 years 6–10 years 11–18 years Adults
Patients, n 21 26 30 162
Age, years  4.1 (1.9–5.9)  7.7 (6.2–9.8) 14.3 (10.6–17.9)  33 (22.0–45.3)
Ristocetin (0.5 mg ml-1), %  1 (1–4)  2 (0–4)  1 (1–3)   1 (0–5)
Ristocetin (1.0 mg ml-1), % 81 (75–97) 82 (68–101) 81 (70–105)  81 (70–97)
Ristocetin (1.5 mg ml-1), % 91 (87–93) 85 (78–99) 85 (72–95)  84 (72–100)
ADP (2.5 μmol l-1),% 76 (69–91) 77 (68–90) 81 (66–104)  80 (69–101)
Collagen (2 μg ml-1), % 75 (64–84) 81 (66–90) 86 (71–100)  81 (69–101)
Collagen (10 μg ml-1), % 83 (74–97) 84 (68–99) 85 (71–102)  86 (73–105)
Collagen (10 μg ml-1), nmola  5.2 (3.8–7.7)  6.0 (4.4–8.9)  6.1 (5.1–8.3)   6.1 (3.7–8.6)
Epinephrine (10 μmol l-1), % 80 (70–91) 81 (73–96) 82 (74–105)  84 (71–100)
Arachidonic (1 nmol l-1), % 79 (73–92) 84 (75–95) 80 (74–102)  84 (73–101)
A-23187 (1 μg ml-1), % 85 (79–88) 74 (68–83) 80 (71–90)  78 (69–99)
aATP release is expressed as the total amount of ATP (μmol) released from 2.5 × 105 platelets per microliter.
ADP = Adenosine diphosphate.
Group <28 days 1–17 years Adults
Patients, n 25 19 35
Age, range 4 days (1–12) 9.3 years (1–17) not determined
ADP (20 μmol l-1), ohms 22.7 ± 7.3 23.5 ± 9.1 18.2 ± 5.6
ADP (20 μmol l-1), nmola 1.30 ± 0.56 1.64 ± 1.1 1.02 ± 0.48
Arachidonic (1 mmol l-1), ohms 23.9 ± 5.4 21.7 ± 8.5 21.3 ± 3.0
Arachidonic (1 mmol l-1), nmola 0.92 ± 0.37 0.79 ± 0.47 0.80 ± 0.26
Collagen (1 μg ml-1), ohms 25.0 ± 6.6 33.4 ± 7.5 33.0 ± 9.7
Collagen (1 μg ml-1), nmola 0.39 ± 0.18 0.91 ± 0.46 0.86 ± 0.24
Thrombina (0.5 U ml-1), nmola 0.93 ± 0.27 1.24 ± 0.64 1.39 ± 0.43
Ristocetin (1.25 mg ml-1), ohms 23.3 ± 8.5 19.6 ± 9.1 27.9 ± 9.4
aATP release is expressed as the total amount of ATP (nmol) released in samples of 450 μl whole 
blood.
ADP = Adenosine diphosphate.
Table 3. Reference values of impedance 
 aggregometry / adenosine triphosphate (ATP) 
release using the Chrono-log lumi-aggregom-
eter in whole blood from healthy children and 
adults. Final concentrations of agonists are 
stated in brackets. Values are expressed as 
mean values ± 1 SD of maximal aggregation 
within 6 min after addition of agonist; table 
modified from [28]
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forming screening tests for platelet function and confirming 
an inherited platelet defect, these children should be referred 
to a nearby diagnostic centre. Because of the broad range of 
possible investigations often needed to evaluate mild to mod-
erate bleeding, a rational and step-by-step approach to diag-
nosis may save time and resources. Such diagnostic centres 
in the German-speaking countries can be located on the web-
site of the GTH (www.gth-online.org/home/paediatrische-gth/
kompetenznetz).
Disclosure
The authors declared no conflict of interest.
than 1 year, LTA in platelet-rich plasma, impedance ag-
gregometry (IA) in whole blood, and luminometric detection 
of adenosine triphosphate release from platelet-dense gran-
ules do not differ from those in adult controls, which suggests 
that established adult normal ranges may be used in children 
beyond 1 year of age (table 2, 3) [28, 29].
Conclusion
Bleeding symptoms such as cutaneous haematoma and 
epistaxis are quite common in children. Evaluation of bleed-
ing history using a standardised questionnaire and a careful, 
clinical examination may enable clinicians to differentiate be-
tween ‘normal’ and a suspected bleeding disorder. After per-
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